Parkinson's disease
Conditions
Interventions
A single oral administration of the investigational product, KK6483C in combination with the existing levodopa (LD)/carbidopa (CD)/entacapone (ET)
Sponsors
Yagi Michio
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Those who have provided voluntary written consent to participate in the study 2) Men aged >= 20 to = 18.5 to < 25.0 at the time of preliminary test
Exclusion criteria
Exclusion criteria: 1) Those with present illness requiring treatment 2) Those with a history of or current drug allergy 3) Those currently having respiratory disease, heart disease, gastrointestinal disease, renal disease, or hepatic disease 4) Those with a history of or current psychiatric disease 5) Those currently having clinically significant orthostatic hypotension 6) Those who have had a bacterial, viral, fungal, or parasitic infection within 28 days prior to signing the informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma drug concentration Pharmacokinetic parameters | — |
Contacts
Public ContactClinical trial information contact
Kyowa Kirin Co., Ltd.
Outcome results
None listed